Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.

GemRIS, an implantable drug delivery system from Taris Biomedical that delivers continuous intravesical gemcitabine, shows potential for use in multiple bladder cancer settings. Ongoing and recently completed phase 1 trials in non-muscle-invasive as well as muscle-invasive bladder cancer are yielding promising preliminary results.

European urology focus. 2019 Sep 24 [Epub ahead of print]

Dominic C Grimberg, Ankeet Shah, Brant A Inman

Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. Electronic address: .

Go Beyond the Abstract and Read a Commentary by the Authors